Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

Objectives The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.Methods Here, w...

Full description

Bibliographic Details
Main Authors: Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
CMV
CMV IgM
multiple myeloma
GMMG-MM5 Phase III Trial
autologous stem cell transplantation
maintenance therapy
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2024.2320006

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2024.2320006

Similar Items